Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors
Linlin Guo(Wuhan Textile University), Ravi Salgia(City Of Hope National Medical Center)
Cited by 26
Related Papers
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion
|Cancer Research|2007|260
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
|Clinical Cancer Research|2007|154